{"title":"疫苗 (Covaxin®) 对不同年龄段人群的有效性：试点研究","authors":"Vivek Chauhan , Adrija Rakshit , Vivek Kumar Dhiman , Gaytri Mahajan , Akash Pnadey , Shamsher Singh Kanwar , Devendra Singh","doi":"10.1016/j.vacun.2023.07.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Covaxin® is a COVID-19 vaccine created and produced by Bharat Biotech in India. The vaccine is based on the strain of SARS-CoV-2 that was first identified in India and has undergone Phase III </span>clinical trials. Covaxin® has been authorized for emergency use in India and has been distributed as part of India's vaccination campaign. The vaccine has been shown to be effective in preventing COVID-19 infection and hospitalization, but additional studies are needed to determine its efficacy as well as safety in the long term.</p></div><div><h3>Methods</h3><p><span><span>The antibody titer against Covaxin® was detected through indirect </span>ELISA </span>immunoassay. Optimization was performed on 500 samples to get an idea and work further on a larger number of samples.</p></div><div><h3>Results</h3><p><span>The vaccine had the best immune response in individuals between the ages of 21 and 30 and the least response in those between 61 and 70. This was attributed to the phenomenon of immunosenescence, which explains the weakening of the </span>immune system<span> with age. Additionally, the study found that the equine anti-CoV-19 serum had a higher binding affinity<span> with Covaxin®, highlighting the effectiveness of horse Ig against COVID-19 antigens.</span></span></p></div><div><h3>Conclusions</h3><p>The study concluded that Covaxin® was effective in generating an immune response in individuals after 2 doses of vaccination; however, the generated immune response decreased with the time of vaccine administration and the age of the vaccinated. The study also showed that the ELISA technique used in this research is an efficient and sensitive method to evaluate vaccine efficiency and can be applied to a larger number of samples for further comparative analysis.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of the vaccine (Covaxin®) on different age groups of people: A pilot study\",\"authors\":\"Vivek Chauhan , Adrija Rakshit , Vivek Kumar Dhiman , Gaytri Mahajan , Akash Pnadey , Shamsher Singh Kanwar , Devendra Singh\",\"doi\":\"10.1016/j.vacun.2023.07.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span>Covaxin® is a COVID-19 vaccine created and produced by Bharat Biotech in India. The vaccine is based on the strain of SARS-CoV-2 that was first identified in India and has undergone Phase III </span>clinical trials. Covaxin® has been authorized for emergency use in India and has been distributed as part of India's vaccination campaign. The vaccine has been shown to be effective in preventing COVID-19 infection and hospitalization, but additional studies are needed to determine its efficacy as well as safety in the long term.</p></div><div><h3>Methods</h3><p><span><span>The antibody titer against Covaxin® was detected through indirect </span>ELISA </span>immunoassay. Optimization was performed on 500 samples to get an idea and work further on a larger number of samples.</p></div><div><h3>Results</h3><p><span>The vaccine had the best immune response in individuals between the ages of 21 and 30 and the least response in those between 61 and 70. This was attributed to the phenomenon of immunosenescence, which explains the weakening of the </span>immune system<span> with age. Additionally, the study found that the equine anti-CoV-19 serum had a higher binding affinity<span> with Covaxin®, highlighting the effectiveness of horse Ig against COVID-19 antigens.</span></span></p></div><div><h3>Conclusions</h3><p>The study concluded that Covaxin® was effective in generating an immune response in individuals after 2 doses of vaccination; however, the generated immune response decreased with the time of vaccine administration and the age of the vaccinated. The study also showed that the ELISA technique used in this research is an efficient and sensitive method to evaluate vaccine efficiency and can be applied to a larger number of samples for further comparative analysis.</p></div>\",\"PeriodicalId\":53407,\"journal\":{\"name\":\"Vacunas\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vacunas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1576988723000663\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1576988723000663","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Effectiveness of the vaccine (Covaxin®) on different age groups of people: A pilot study
Background
Covaxin® is a COVID-19 vaccine created and produced by Bharat Biotech in India. The vaccine is based on the strain of SARS-CoV-2 that was first identified in India and has undergone Phase III clinical trials. Covaxin® has been authorized for emergency use in India and has been distributed as part of India's vaccination campaign. The vaccine has been shown to be effective in preventing COVID-19 infection and hospitalization, but additional studies are needed to determine its efficacy as well as safety in the long term.
Methods
The antibody titer against Covaxin® was detected through indirect ELISA immunoassay. Optimization was performed on 500 samples to get an idea and work further on a larger number of samples.
Results
The vaccine had the best immune response in individuals between the ages of 21 and 30 and the least response in those between 61 and 70. This was attributed to the phenomenon of immunosenescence, which explains the weakening of the immune system with age. Additionally, the study found that the equine anti-CoV-19 serum had a higher binding affinity with Covaxin®, highlighting the effectiveness of horse Ig against COVID-19 antigens.
Conclusions
The study concluded that Covaxin® was effective in generating an immune response in individuals after 2 doses of vaccination; however, the generated immune response decreased with the time of vaccine administration and the age of the vaccinated. The study also showed that the ELISA technique used in this research is an efficient and sensitive method to evaluate vaccine efficiency and can be applied to a larger number of samples for further comparative analysis.
期刊介绍：
Sin duda una de las mejores publicaciones para conocer los avances en el campo de las vacunaciones preventivas, tanto en el ámbito de la investigación básica como aplicada y en la evaluación de programas de vacunaciones. Su alta calidad y utilidad la ha llevado a estar indexada en los prestigiosos índices IME y SCOPUS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
